Difference between revisions of "Tivozanib (Fotivda)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "http://ascopubs.org/doi/abs/" to "http://ascopubs.org/doi/full/") |
Warner-admin (talk | contribs) m (Text replacement - "Category:VEGF inhibitors" to "Category:VEGFR inhbitors") |
||
| Line 11: | Line 11: | ||
[[Category:Investigational]] | [[Category:Investigational]] | ||
| − | [[Category: | + | [[Category:VEGFR inhbitors]] |
Revision as of 18:57, 30 January 2018
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplastic activities. Tivozanib binds to and inhibits VEGFRs 1, 2 and 3, which may result in the inhibition of endothelial cell migration and proliferation, inhibition of tumor angiogenesis and tumor cell death.
Preliminary data
Renal cancer
- Motzer RJ, Nosov D, Eisen T, Bondarenko I, Lesovoy V, Lipatov O, Tomczak P, Lyulko O, Alyasova A, Harza M, Kogan M, Alekseev BY, Sternberg CN, Szczylik C, Cella D, Ivanescu C, Krivoshik A, Strahs A, Esteves B, Berkenblit A, Hutson TE. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol. 2013 Oct 20;31(30):3791-9. Epub 2013 Sep 9. link to original article PubMed